ESR1 and ductal breast carcinoma in situ: In comparison to female breast cancer (FBC), a higher prevalence of estrogen-receptor positivity and only a 9% rate of HER2 (human epidermal growth factor receptor 2)-positive tumors is reported in the literature for MBC, with 10% of cases presenting as ductal carcinoma in situ (DCIS) [8].